Association of BRAF V600E Status of Incident Melanoma and Risk for a Second Primary Malignancy: A Population-Based Study

Abstract

Dermatologists should be aware of the long-term risk of second primary malignancies after an incident melanoma.• BRAF mutations occur in melanomas and several other cancers. Our study found that melanoma BRAF V600E expression is associated with an increased risk for basal cell carcinomas.

Risk of Second Primary Malignancies in Melanoma Survivors: A Population-Based Study

“…Relative to its genetic origin, as commented before, mutations in the BRAF oncogene are found in approximately 50% of MM, but they are also observed in other cancers such as hairy cell leukemia, papillary thyroid cancers, colorectal cancer, liver cancer, brain cancer, lung cancer, soft tissue cancer, ovarian cancer, and breast cancer, with varying rates ranging from 2% to 100% [28]. However, there is no established association between BRAF positivity in previous MM and the development of SPNs, possibly due to the somatic nature of the mutation rather than being inherited or germline [28]. On the other hand, germline mutations in BRCA2 or CDKN2A have been suggested as explanations for the link between MM and breast cancer, and CDKN2A mutations have also been proposed as a cause of the increased risk of pancreatic cancer.…”

“…On the other hand, germline mutations in BRCA2 or CDKN2A have been suggested as explanations for the link between MM and breast cancer, and CDKN2A mutations have also been proposed as a cause of the increased risk of pancreatic cancer. Additionally, TSPY gene mutations have been observed in both MM and prostate cancer [28].…”

New pyrazolylindolin-2-one based coumarin derivatives as anti-melanoma agents: design, synthesis, dual BRAFV600E/VEGFR-2 inhibition, and computational studies

“…9,10 This mutation is mostly associated with melanoma. [11][12][13] The successful inhibition of BRAF was a turning point in the development of anti-melanoma agents. Targeted therapy with BRAF inhibitors represents a milestone in the treatment of metastatic melanoma that harbors BRAF V600E mutations.…”